Literature DB >> 12975579

Glucocorticoid-induced apoptosis in human eosinophils: mechanisms of action.

A Druilhe1, S Létuvé, M Pretolani.   

Abstract

Prominent blood and tissue eosinophilia is clinically manifested in a number of inflammatory states, particularly in allergic diseases. Corticosteroids are the most effective anti-inflammatory drugs used in the treatment of eosinophilic disorders, including bronchial asthma. Their beneficial effects result, among others, from (i) the suppression of the synthesis and the effects of eosinophil survival factors, (ii) the direct induction of eosinophil apoptosis and (iii) the stimulation of their engulfment by professional phagocytic cells. Failure of steroids to propagate apoptotic signals and to promote eosinophil clearance may explain the corticoresistance observed in a proportion of asthmatic patients. Accordingly, studies on the intracellular mechanisms involved in eosinophil corticosensitivity and resistance may provide a valuable tool for identifying new and selective molecular targets to therapeutically resolve otherwise persistent eosinophilic inflammation. In this review, the intracellular cascade of events involved in corticosteroid-mediated eosinophil apoptotic death is discussed and compared to the signalling pathway governing this process in the established model of dexamethasone-induced thymocyte apoptosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12975579     DOI: 10.1023/a:1025590308147

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  49 in total

1.  Glucocorticoid-induced eosinopenia in humans can be linked to early transcriptional events.

Authors:  P Khoury; K Stokes; M Gadkari; M A Makiya; F Legrand; Z Hu; A Klion; L M Franco
Journal:  Allergy       Date:  2018-07-17       Impact factor: 13.146

Review 2.  Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders.

Authors:  Steven J Ackerman; Bruce S Bochner
Journal:  Immunol Allergy Clin North Am       Date:  2007-08       Impact factor: 3.479

Review 3.  Immune regulation by glucocorticoids.

Authors:  Derek W Cain; John A Cidlowski
Journal:  Nat Rev Immunol       Date:  2017-02-13       Impact factor: 53.106

4.  Lactogens protect rodent and human beta cells against glucolipotoxicity-induced cell death through Janus kinase-2 (JAK2)/signal transducer and activator of transcription-5 (STAT5) signalling.

Authors:  N Guthalu Kondegowda; A Mozar; C Chin; A Otero; A Garcia-Ocaña; R C Vasavada
Journal:  Diabetologia       Date:  2012-03-03       Impact factor: 10.122

Review 5.  Activation of Human Eosinophils with Nanoparticles: a New Area of Research.

Authors:  Marion Vanharen; Denis Girard
Journal:  Inflammation       Date:  2020-02       Impact factor: 4.092

Review 6.  T cell co-stimulatory molecules: a co-conspirator in the pathogenesis of eosinophilic esophagitis?

Authors:  Zili Zhang; Thomas J Sferra; Yasemen Eroglu
Journal:  Dig Dis Sci       Date:  2013-03-02       Impact factor: 3.199

7.  Corticosteroids and montelukast: effects on airway epithelial and human umbilical vein endothelial cells.

Authors:  K Andersson; E B Shebani; N Makeeva; G M Roomans; Z Servetnyk
Journal:  Lung       Date:  2010-01-16       Impact factor: 2.584

8.  Early phase resolution of mucosal eosinophilic inflammation in allergic rhinitis.

Authors:  Lena Uller; Cecilia Ahlström Emanuelsson; Morgan Andersson; Jonas S Erjefält; Lennart Greiff; Carl G Persson
Journal:  Respir Res       Date:  2010-05-09

9.  Histone deacetylase inhibitors induce apoptosis in human eosinophils and neutrophils.

Authors:  Hannu Kankaanranta; Mirkka Janka-Junttila; Pinja Ilmarinen-Salo; Kazuhiro Ito; Ulla Jalonen; Misako Ito; Ian M Adcock; Eeva Moilanen; Xianzhi Zhang
Journal:  J Inflamm (Lond)       Date:  2010-02-04       Impact factor: 4.981

Review 10.  Targeting eosinophils in allergy, inflammation and beyond.

Authors:  Patricia C Fulkerson; Marc E Rothenberg
Journal:  Nat Rev Drug Discov       Date:  2013-01-21       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.